Giles Tully is CEO of PinPoint Data Science, the team behind the ‘PinPoint Test’ – an AI (Artificial Intelligence) driven blood test for cancer that aims to transform urgent cancer referrals in the NHS.
Since becoming CEO in 2017, Giles has taken a largely part-time team of scientists with a great idea and grown PinPoint into a dynamic, professional team with a burgeoning reputation. Applying his broad entrepreneurial background to a complex field, he has been able to translate the potential of machine learning in cancer diagnostics to inspire investors and secure the support of national bodies such as Innovate UK and SBRI Healthcare.